^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ROSE12

    i
    Other names: ROSE12, ROSE 12, ROSE-12
    Associations

    News

    Trials
    Company:
    Roche
    Drug class:
    CTLA4 inhibitor, Treg cell depleter
    Related drugs:
    Associations

    News

    Trials
    12d
    ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation. (PubMed, J Immunother Cancer)
    These findings support the clinical development of ROSE12 as a tumor-selective Treg-depleting immunotherapy with potential efficacy in programmed cell death protein-1/PD-L1 therapy-resistant patients. The favorable safety profile was attributed to the ATP-dependent binding mechanism that restricts activity to the high-ATP tumor microenvironment. ROSE12 is currently being evaluated in phase I clinical trials (NCT05907980).
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    Yervoy (ipilimumab) • ROSE12
    over2years
    A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=219, Recruiting, Chugai Pharmaceutical
    New P1 trial • Combination therapy • Metastases
    |
    Tecentriq (atezolizumab) • ROSE12